The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia

Two major advances in the management of febrile neutropenia (FN) associated with cancer therapy occurred during the last 30 years. First, the stratification of patients with FN, according to the risk of complications, allowed more simple and less expensive management. Second, the prophylactic use of...

Full description

Saved in:
Bibliographic Details
Published in:Supportive care in cancer 2013-06, Vol.21 (6), p.1793-1795
Main Authors: Klastersky, Jean, Raftopoulos, Harry, Rapoport, Bernardo
Format: Article
Language:English
Subjects:
Antineoplastic Agents - adverse effects
Cancer
Care and treatment
Chemotherapy
Conferences
Febrile Neutropenia - chemically induced
Febrile Neutropenia - drug therapy
Febrile Neutropenia - prevention & control
Granulocyte Colony-Stimulating Factor - therapeutic use
Health aspects
Humans
Leukocytes
Medical research
Medicine
Medicine & Public Health
Medicine, Experimental
Neoplasms - drug therapy
Neutropenia
Neutrophils - drug effects
Neutrophils - immunology
Nursing
Nursing Research
Oncology
Opportunistic Infections - immunology
Opportunistic Infections - prevention & control
Pain Medicine
Prevention
Preventive medicine
Rehabilitation Medicine
Side effects
Special Article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Two major advances in the management of febrile neutropenia (FN) associated with cancer therapy occurred during the last 30 years. First, the stratification of patients with FN, according to the risk of complications, allowed more simple and less expensive management. Second, the prophylactic use of granulocyte colony-stimulating factors provided a physiological way to reduce the incidence of severe granulocytopenia. These questions have been the focus of a symposium organized by the FN/ID Study Group during the recent annual Multinational Association of Supportive Care in Cancer meeting.
ISSN:0941-4355
1433-7339
DOI:10.1007/s00520-013-1776-9